Education
About Us
Working with TipRanks
Follow Us
David Shook Insider Profile
4 Followers
David Shook, Chief Medical Officer, Head of Research & Development at Nkarta, holds 21.90K shares in Lyell Immunopharma (Ticker: LYEL), holds 190.96K shares in Nkarta (Ticker: NKTX).
David Shook Nkarta (NKTX)Chief Medical Officer, Head of Research & Development
Nkarta (NKTX)
Chief Medical Officer, Head of Research & Development
Ranked #83,398 out of 103,225 Corporate Insiders
Profitable Transactions
3 out of 5 Profitable Transactions
Average Return
-22.90%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that David Shook holds in companies
Most Profitable Insider Trade
The most profitable trade made by David Shook
David Shook's Trading History
Nkarta
Jan 17, 2025
Chief Medical Officer, Head of Research & Development
Informative Sell
19.00K
$404.82K
Lyell Immunopharma
Jun 11, 2025
Chief Medical Officer
Uninformative Buy
―
$242.65K
List of latest transactions for each holding click on a transaction to see David Shook's performance on stock
You May Also Like
David Shook insider profile FAQ
What is the percentage of profitable transactions made by David Shook?
The percentage of profitable transactions made by David Shook is 60%.
What is the average return per transaction made by David Shook?
The average return per transaction made by David Shook is -22.90%.
What stocks does David Shook hold?
David Shook holds: NKTX, LYEL stocks.
What was David Shook’s latest transaction?
David Shook latest transaction was an Uninformative Buy of ―.
What was David Shook's most profitable transaction?
David Shook’s most profitable transaction was an Informative Sell of NKTX stock on January 18, 2024. The return on the trade was 70.90%.
What is David Shook's role in Nkarta?
David Shook's role in Nkarta is Chief Medical Officer, Head of Research & Development.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.